AU2014354808A1 - Personalized medicine approach for treating cognitive loss - Google Patents

Personalized medicine approach for treating cognitive loss Download PDF

Info

Publication number: AU2014354808A1
Authority: AU; Australia
Prior art keywords: endophenotype; neurotrophic; metabolic; expression; biomarkers
Prior art date: 2013-11-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2014354808A

Other languages

English (en)

Inventor

Sid E. O'bryant

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of North Texas Health Science Center

Original Assignee

University of North Texas Health Science Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-11-26

Filing date

2014-11-26

Publication date

2016-06-02

2014-11-26 Application filed by University of North Texas Health Science Center filed Critical University of North Texas Health Science Center

2016-06-02 Publication of AU2014354808A1 publication Critical patent/AU2014354808A1/en

2018-02-13 Priority to AU2018201062A priority Critical patent/AU2018201062B2/en

2020-09-24 Priority to AU2020239715A priority patent/AU2020239715B2/en

Status Abandoned legal-status Critical Current

Links

230000001149 cognitive effect Effects 0.000 title claims abstract description 186
239000003814 drug Substances 0.000 title claims description 185
238000013459 approach Methods 0.000 title description 24
238000000034 method Methods 0.000 claims abstract description 256
238000011282 treatment Methods 0.000 claims abstract description 171
239000000090 biomarker Substances 0.000 claims abstract description 161
230000002503 metabolic effect Effects 0.000 claims abstract description 131
230000000508 neurotrophic effect Effects 0.000 claims abstract description 125
230000019771 cognition Effects 0.000 claims abstract description 52
238000002560 therapeutic procedure Methods 0.000 claims abstract description 41
230000003001 depressive effect Effects 0.000 claims abstract description 38
230000002265 prevention Effects 0.000 claims abstract description 31
230000002757 inflammatory effect Effects 0.000 claims abstract description 28
230000004064 dysfunction Effects 0.000 claims abstract description 7
208000010877 cognitive disease Diseases 0.000 claims description 168
229940079593 drug Drugs 0.000 claims description 161
230000000770 proinflammatory effect Effects 0.000 claims description 153
208000024827 Alzheimer disease Diseases 0.000 claims description 132
230000014509 gene expression Effects 0.000 claims description 132
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 93
201000010099 disease Diseases 0.000 claims description 89
230000004044 response Effects 0.000 claims description 87
238000003491 array Methods 0.000 claims description 72
102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 51
108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 51
229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 51
102000030914 Fatty Acid-Binding Human genes 0.000 claims description 47
108010025020 Nerve Growth Factor Proteins 0.000 claims description 47
108091022862 fatty acid binding Proteins 0.000 claims description 47
208000020832 chronic kidney disease Diseases 0.000 claims description 43
210000002966 serum Anatomy 0.000 claims description 42
238000002483 medication Methods 0.000 claims description 41
239000000902 placebo Substances 0.000 claims description 41
229940068196 placebo Drugs 0.000 claims description 41
208000018737 Parkinson disease Diseases 0.000 claims description 39
210000004369 blood Anatomy 0.000 claims description 37
206010012601 diabetes mellitus Diseases 0.000 claims description 37
108010074051 C-Reactive Protein Proteins 0.000 claims description 36
102100032752 C-reactive protein Human genes 0.000 claims description 36
239000008280 blood Substances 0.000 claims description 36
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 33
201000006417 multiple sclerosis Diseases 0.000 claims description 32
208000030886 Traumatic Brain injury Diseases 0.000 claims description 30
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 30
230000008859 change Effects 0.000 claims description 30
230000009529 traumatic brain injury Effects 0.000 claims description 30
HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims description 28
201000002832 Lewy body dementia Diseases 0.000 claims description 28
102000018886 Pancreatic Polypeptide Human genes 0.000 claims description 28
101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims description 28
201000011240 Frontotemporal dementia Diseases 0.000 claims description 26
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 26
229940053128 nerve growth factor Drugs 0.000 claims description 26
230000003818 metabolic dysfunction Effects 0.000 claims description 25
108090000623 proteins and genes Proteins 0.000 claims description 25
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 24
-1 ICAM1 Proteins 0.000 claims description 23
230000032683 aging Effects 0.000 claims description 23
230000003110 anti-inflammatory effect Effects 0.000 claims description 23
201000000980 schizophrenia Diseases 0.000 claims description 23
102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 22
108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 22
239000003472 antidiabetic agent Substances 0.000 claims description 22
201000010374 Down Syndrome Diseases 0.000 claims description 21
208000032928 Dyslipidaemia Diseases 0.000 claims description 21
206010020772 Hypertension Diseases 0.000 claims description 21
208000017170 Lipid metabolism disease Diseases 0.000 claims description 21
102000007072 Nerve Growth Factors Human genes 0.000 claims description 21
206010044688 Trisomy 21 Diseases 0.000 claims description 21
230000003930 cognitive ability Effects 0.000 claims description 21
239000003900 neurotrophic factor Substances 0.000 claims description 21
206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 20
238000004422 calculation algorithm Methods 0.000 claims description 20
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
102000004169 proteins and genes Human genes 0.000 claims description 20
208000020925 Bipolar disease Diseases 0.000 claims description 19
102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 19
108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 19
102000015779 HDL Lipoproteins Human genes 0.000 claims description 19
108010010234 HDL Lipoproteins Proteins 0.000 claims description 19
208000006011 Stroke Diseases 0.000 claims description 19
102000007330 LDL Lipoproteins Human genes 0.000 claims description 18
108010007622 LDL Lipoproteins Proteins 0.000 claims description 18
230000002255 enzymatic effect Effects 0.000 claims description 18
208000010125 myocardial infarction Diseases 0.000 claims description 18
208000020016 psychiatric disease Diseases 0.000 claims description 18
208000028698 Cognitive impairment Diseases 0.000 claims description 17
102000007000 Tenascin Human genes 0.000 claims description 17
108010008125 Tenascin Proteins 0.000 claims description 17
230000001430 anti-depressive effect Effects 0.000 claims description 16
230000003178 anti-diabetic effect Effects 0.000 claims description 16
239000000935 antidepressant agent Substances 0.000 claims description 16
230000008901 benefit Effects 0.000 claims description 16
230000007423 decrease Effects 0.000 claims description 16
229940124597 therapeutic agent Drugs 0.000 claims description 16
101800000224 Glucagon-like peptide 1 Proteins 0.000 claims description 15
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 15
102100040918 Pro-glucagon Human genes 0.000 claims description 15
239000000556 agonist Substances 0.000 claims description 15
108010023321 Factor VII Proteins 0.000 claims description 14
YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 claims description 13
102000004877 Insulin Human genes 0.000 claims description 13
108090001061 Insulin Proteins 0.000 claims description 13
102100029909 Peptide YY Human genes 0.000 claims description 13
108010088847 Peptide YY Proteins 0.000 claims description 13
238000001378 electrochemiluminescence detection Methods 0.000 claims description 13
229940125396 insulin Drugs 0.000 claims description 13
238000007637 random forest analysis Methods 0.000 claims description 13
238000012706 support-vector machine Methods 0.000 claims description 13
102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 claims description 12
101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 claims description 12
108700028369 Alleles Proteins 0.000 claims description 12
102100023698 C-C motif chemokine 17 Human genes 0.000 claims description 12
102100036845 C-C motif chemokine 22 Human genes 0.000 claims description 12
108010083701 Chemokine CCL22 Proteins 0.000 claims description 12
102100023804 Coagulation factor VII Human genes 0.000 claims description 12
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 claims description 12
108090000174 Interleukin-10 Proteins 0.000 claims description 12
102000003814 Interleukin-10 Human genes 0.000 claims description 12
101150014691 PPARA gene Proteins 0.000 claims description 12
238000010240 RT-PCR analysis Methods 0.000 claims description 12
229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 12
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 12
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 12
239000005557 antagonist Substances 0.000 claims description 12
229940005513 antidepressants Drugs 0.000 claims description 12
238000003556 assay Methods 0.000 claims description 12
239000011324 bead Substances 0.000 claims description 12
238000002038 chemiluminescence detection Methods 0.000 claims description 12
238000000556 factor analysis Methods 0.000 claims description 12
229940012413 factor vii Drugs 0.000 claims description 12
238000001917 fluorescence detection Methods 0.000 claims description 12
239000008103 glucose Substances 0.000 claims description 12
239000007791 liquid phase Substances 0.000 claims description 12
238000002493 microarray Methods 0.000 claims description 12
229920001184 polypeptide Polymers 0.000 claims description 12
238000000513 principal component analysis Methods 0.000 claims description 12
108090000765 processed proteins & peptides Proteins 0.000 claims description 12
102000004196 processed proteins & peptides Human genes 0.000 claims description 12
238000000163 radioactive labelling Methods 0.000 claims description 12
102000005962 receptors Human genes 0.000 claims description 12
108020003175 receptors Proteins 0.000 claims description 12
239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 12
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 12
229940076279 serotonin Drugs 0.000 claims description 12
239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 12
239000007790 solid phase Substances 0.000 claims description 12
238000012546 transfer Methods 0.000 claims description 12
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 10
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 10
102000003802 alpha-Synuclein Human genes 0.000 claims description 10
108090000185 alpha-Synuclein Proteins 0.000 claims description 10
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 10
235000012000 cholesterol Nutrition 0.000 claims description 10
230000004060 metabolic process Effects 0.000 claims description 10
150000003626 triacylglycerols Chemical class 0.000 claims description 10
102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 9
108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 9
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 9
102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 9
108010002616 Interleukin-5 Proteins 0.000 claims description 9
108090001005 Interleukin-6 Proteins 0.000 claims description 9
102000048238 Neuregulin-1 Human genes 0.000 claims description 9
108090000556 Neuregulin-1 Proteins 0.000 claims description 9
102000036693 Thrombopoietin Human genes 0.000 claims description 9
108010041111 Thrombopoietin Proteins 0.000 claims description 9
229940123445 Tricyclic antidepressant Drugs 0.000 claims description 9
102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 9
101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 9
102000015736 beta 2-Microglobulin Human genes 0.000 claims description 9
108010081355 beta 2-Microglobulin Proteins 0.000 claims description 9
230000006999 cognitive decline Effects 0.000 claims description 9
238000012216 screening Methods 0.000 claims description 9
239000003029 tricyclic antidepressant agent Substances 0.000 claims description 9
102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 8
102000003810 Interleukin-18 Human genes 0.000 claims description 8
108090000171 Interleukin-18 Proteins 0.000 claims description 8
102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 8
108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 8
230000002411 adverse Effects 0.000 claims description 8
108091005995 glycated hemoglobin Proteins 0.000 claims description 8
102100021935 C-C motif chemokine 26 Human genes 0.000 claims description 7
108010083698 Chemokine CCL26 Proteins 0.000 claims description 7
102000000743 Interleukin-5 Human genes 0.000 claims description 7
102000004889 Interleukin-6 Human genes 0.000 claims description 7
102000000704 Interleukin-7 Human genes 0.000 claims description 7
108010002586 Interleukin-7 Proteins 0.000 claims description 7
230000006735 deficit Effects 0.000 claims description 7
238000011156 evaluation Methods 0.000 claims description 7
238000005259 measurement Methods 0.000 claims description 7
150000003431 steroids Chemical class 0.000 claims description 7
101150013553 CD40 gene Proteins 0.000 claims description 6
102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 claims description 6
108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 claims description 6
102000051325 Glucagon Human genes 0.000 claims description 6
108060003199 Glucagon Proteins 0.000 claims description 6
102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 claims description 6
108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 claims description 6
108090001007 Interleukin-8 Proteins 0.000 claims description 6
102000004890 Interleukin-8 Human genes 0.000 claims description 6
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims description 6
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims description 6
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims description 6
108010016731 PPAR gamma Proteins 0.000 claims description 6
102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 6
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 6
230000007370 cognitive improvement Effects 0.000 claims description 6
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 6
229960004666 glucagon Drugs 0.000 claims description 6
239000003862 glucocorticoid Substances 0.000 claims description 6
238000003018 immunoassay Methods 0.000 claims description 6
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 6
229940037128 systemic glucocorticoids Drugs 0.000 claims description 6
102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 5
108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 5
102000015696 Interleukins Human genes 0.000 claims description 4
108010063738 Interleukins Proteins 0.000 claims description 4
229940127003 anti-diabetic drug Drugs 0.000 claims description 4
230000001399 anti-metabolic effect Effects 0.000 claims description 4
238000009207 exercise therapy Methods 0.000 claims description 4
230000002218 hypoglycaemic effect Effects 0.000 claims description 4
238000002626 targeted therapy Methods 0.000 claims description 3
102000003390 tumor necrosis factor Human genes 0.000 claims description 3
KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 2
102000016519 Coagulation factor VII Human genes 0.000 claims description 2
102100037499 Parkinson disease protein 7 Human genes 0.000 claims description 2
108010032428 Protein Deglycase DJ-1 Proteins 0.000 claims description 2
238000011861 anti-inflammatory therapy Methods 0.000 claims description 2
229940105772 coagulation factor vii Drugs 0.000 claims description 2
230000003834 intracellular effect Effects 0.000 claims description 2
102000015336 Nerve Growth Factor Human genes 0.000 claims 13
102100032277 Serum amyloid A-1 protein Human genes 0.000 claims 5
102000019034 Chemokines Human genes 0.000 claims 1
108010012236 Chemokines Proteins 0.000 claims 1
101000869480 Homo sapiens Serum amyloid A-1 protein Proteins 0.000 claims 1
239000003446 ligand Substances 0.000 claims 1
208000027061 mild cognitive impairment Diseases 0.000 description 94
239000000523 sample Substances 0.000 description 59
108060006698 EGF receptor Proteins 0.000 description 22
206010012289 Dementia Diseases 0.000 description 21
238000012360 testing method Methods 0.000 description 20
210000002381 plasma Anatomy 0.000 description 19
230000015654 memory Effects 0.000 description 17
238000004458 analytical method Methods 0.000 description 16
238000003745 diagnosis Methods 0.000 description 15
208000015122 neurodegenerative disease Diseases 0.000 description 15
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 15
208000012902 Nervous system disease Diseases 0.000 description 14
208000025966 Neurological disease Diseases 0.000 description 14
102100023995 Beta-nerve growth factor Human genes 0.000 description 13
230000004770 neurodegeneration Effects 0.000 description 11
230000006870 function Effects 0.000 description 10
239000012071 phase Substances 0.000 description 10
239000002260 anti-inflammatory agent Substances 0.000 description 8
229940124599 anti-inflammatory drug Drugs 0.000 description 8
210000001175 cerebrospinal fluid Anatomy 0.000 description 8
230000003247 decreasing effect Effects 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 7
230000003111 delayed effect Effects 0.000 description 7
230000006872 improvement Effects 0.000 description 7
230000004054 inflammatory process Effects 0.000 description 7
238000007477 logistic regression Methods 0.000 description 7
239000000203 mixture Substances 0.000 description 7
230000000670 limiting effect Effects 0.000 description 6
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
230000003920 cognitive function Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
201000000523 end stage renal failure Diseases 0.000 description 5
230000036541 health Effects 0.000 description 5
238000012545 processing Methods 0.000 description 5
206010048554 Endothelial dysfunction Diseases 0.000 description 4
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 4
239000000117 blood based biomarker Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000013461 design Methods 0.000 description 4
238000001514 detection method Methods 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
208000028208 end stage renal disease Diseases 0.000 description 4
230000008694 endothelial dysfunction Effects 0.000 description 4
239000003550 marker Substances 0.000 description 4
230000007087 memory ability Effects 0.000 description 4
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 4
229960002009 naproxen Drugs 0.000 description 4
230000000926 neurological effect Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
238000012034 trail making test Methods 0.000 description 4
206010061818 Disease progression Diseases 0.000 description 3
101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
208000029560 autism spectrum disease Diseases 0.000 description 3
230000008236 biological pathway Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
230000005750 disease progression Effects 0.000 description 3
230000010326 executive functioning Effects 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
230000008449 language Effects 0.000 description 3
230000007334 memory performance Effects 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000012549 training Methods 0.000 description 3
230000007497 verbal memory Effects 0.000 description 3
206010001580 Albuminuria Diseases 0.000 description 2
101000726738 Canis lupus familiaris Homeobox protein cut-like 1 Proteins 0.000 description 2
108700011259 MicroRNAs Proteins 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
229960000590 celecoxib Drugs 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000037411 cognitive enhancing Effects 0.000 description 2
238000002790 cross-validation Methods 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
229940126904 hypoglycaemic agent Drugs 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
239000002679 microRNA Substances 0.000 description 2
230000000626 neurodegenerative effect Effects 0.000 description 2
230000007171 neuropathology Effects 0.000 description 2
230000003557 neuropsychological effect Effects 0.000 description 2
238000010855 neuropsychological testing Methods 0.000 description 2
230000007170 pathology Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000011285 therapeutic regimen Methods 0.000 description 2
238000010200 validation analysis Methods 0.000 description 2
238000010176 18-FDG-positron emission tomography Methods 0.000 description 1
ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 1
101150037123 APOE gene Proteins 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102100029470 Apolipoprotein E Human genes 0.000 description 1
102100039986 Apoptosis inhibitor 5 Human genes 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
206010011469 Crying Diseases 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
229940124602 FDA-approved drug Drugs 0.000 description 1
108010014172 Factor V Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
101000959871 Homo sapiens Apoptosis inhibitor 5 Proteins 0.000 description 1
208000009829 Lewy Body Disease Diseases 0.000 description 1
208000001145 Metabolic Syndrome Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
208000024799 Thyroid disease Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
238000011256 aggressive treatment Methods 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
230000007278 cognition impairment Effects 0.000 description 1
230000004633 cognitive health Effects 0.000 description 1
231100000870 cognitive problem Toxicity 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000013211 curve analysis Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000005611 electricity Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
230000005548 health behavior Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000002610 neuroimaging Methods 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000000803 paradoxical effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
230000005195 poor health Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000007670 refining Methods 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
208000021510 thyroid gland disease Diseases 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
238000009424 underpinning Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000001755 vocal effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Medical Informatics (AREA)
Physics & Mathematics (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Data Mining & Analysis (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Databases & Information Systems (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Pathology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Software Systems (AREA)
Computer Vision & Pattern Recognition (AREA)
Theoretical Computer Science (AREA)
Artificial Intelligence (AREA)
Evolutionary Biology (AREA)
Bioinformatics & Computational Biology (AREA)
Bioethics (AREA)
Spectroscopy & Molecular Physics (AREA)
Evolutionary Computation (AREA)
Wood Science & Technology (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Primary Health Care (AREA)

AU2014354808A 2013-11-26 2014-11-26 Personalized medicine approach for treating cognitive loss Abandoned AU2014354808A1 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
AU2018201062A AU2018201062B2 (en)	2013-11-26	2018-02-13	Personalized medicine approach for treating cognitive loss
AU2020239715A AU2020239715B2 (en)	2013-11-26	2020-09-24	Personalized medicine approach for treating cognitive loss

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361908812P	2013-11-26	2013-11-26
US61/908,812		2013-11-26
PCT/US2014/067562 WO2015081166A1 (fr)	2013-11-26	2014-11-26	Approche médicale personnalisée pour le traitement d'une perte cognitive

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2018201062A Division AU2018201062B2 (en)	2013-11-26	2018-02-13	Personalized medicine approach for treating cognitive loss

Publications (1)

Publication Number	Publication Date
AU2014354808A1 true AU2014354808A1 (en)	2016-06-02

Family

ID=53199628

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AU2014354808A Abandoned AU2014354808A1 (en)	2013-11-26	2014-11-26	Personalized medicine approach for treating cognitive loss
AU2018201062A Active AU2018201062B2 (en)	2013-11-26	2018-02-13	Personalized medicine approach for treating cognitive loss
AU2020239715A Active AU2020239715B2 (en)	2013-11-26	2020-09-24	Personalized medicine approach for treating cognitive loss

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
AU2018201062A Active AU2018201062B2 (en)	2013-11-26	2018-02-13	Personalized medicine approach for treating cognitive loss
AU2020239715A Active AU2020239715B2 (en)	2013-11-26	2020-09-24	Personalized medicine approach for treating cognitive loss

Country Status (6)

Country	Link
US (3)	US11885816B2 (fr)
EP (1)	EP3074525B1 (fr)
JP (1)	JP6364488B2 (fr)
AU (3)	AU2014354808A1 (fr)
CA (2)	CA2930874A1 (fr)
WO (1)	WO2015081166A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10487148B2 (en)	2010-01-28	2019-11-26	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for treating aging-associated impairments
US20160208011A1 (en)	2010-01-28	2016-07-21	The Board Of Trustees Of The Leland Stanford Junior University	Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2017120461A1 (fr)	2016-01-08	2017-07-13	The Board Of Trustees Of The Leland Stanford Junior University	Modulation du ccr3 pour le traitement de déficiences associées au vieillissement, et compositions utilisées pour cette modulation
US9161968B2 (en)	2011-04-08	2015-10-20	The Board Of Trustees Of The Leland Stanford Junior University	Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
EP3751283A3 (fr)	2013-07-11	2021-03-24	University of North Texas Health Science Center at Fort Worth	Dépistage basé sur le sang pour la détection d'une maladie neurologique dans des installations de soins primaires
WO2015081166A1 (fr)	2013-11-26	2015-06-04	University Of North Texas Health Science Center At Fort Worth	Approche médicale personnalisée pour le traitement d'une perte cognitive
WO2022187670A1 (fr) *	2021-03-05	2022-09-09	University Of North Texas Health Science Center At Fort Worth	Approche médicale personnalisée permettant le traitement d'une perte cognitive
US10688130B2 (en)	2013-12-09	2020-06-23	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for treating aging-associated conditions
US10905779B2 (en)	2013-12-09	2021-02-02	The Board Of Trustees Of The Leland Stanford Junior University	Methods for screening human blood products comprising plasma using immunocompromised rodent models
US10796802B1 (en)	2015-05-01	2020-10-06	Cerner Innovations, Inc.	Computer decision support for determining surgery candidacy in stage four chronic kidney disease
EP3297702A4 (fr) *	2015-05-18	2019-01-16	The Board of Trustees of The Leland Stanford Junior University	Méthodes et compositions permettant de traiter des troubles associés au vieillissement
ES2944446T3 (es) *	2015-06-08	2023-06-21	Univ California	Uso de la modulación de H3K9me3 para potenciar la función cognitiva
DK3307296T3 (da)	2015-06-15	2021-12-13	Univ Leland Stanford Junior	Timp2 til anvendelse til behandling af aldringsassocierede tilstande
US20180268940A1 (en) *	2015-09-25	2018-09-20	Buck Institute For Research On Aging	Compositions and methods for specific biological cognitive functions in neurodegenerative diseases
CN116359503A (zh)	2016-09-19	2023-06-30	血液学有限公司	用于使用多维分析检测异常细胞的系统、方法和制品
US11605093B1 (en)	2017-02-22	2023-03-14	Amazon Technologies, Inc.	Security policy enforcement
WO2019049705A1 (fr) *	2017-09-08	2019-03-14	自然免疫制御技術研究組合	Dispositif et procédé de diagnostic de symptômes de la maladie d'alzheimer
JP7412003B2 (ja) *	2018-01-18	2024-01-12	ユニバーシティーオブノーステキサスヘルスサイエンスセンターアットフォートワース	アルツハイマー病に罹患している患者の特定の亜集団を治療するためのｎｓａｉｄ及びドネペジルについてのコンパニオン診断
EP3762730A4 (fr) *	2018-03-05	2021-12-01	The Board of Trustees of the Leland Stanford Junior University	Apprentissage automatique et procédés basés sur une simulation moléculaire pour améliorer la prévision de liaison et d'activité
EP3762405A4 (fr)	2018-03-05	2021-12-01	The Board of Trustees of the Leland Stanford Junior University	Systèmes et procédés pour convolutions graphiques spatiales ayant des applications dans la découverte de médicaments et la simulation moléculaire
WO2020006445A1 (fr)	2018-06-29	2020-01-02	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Biomarqueurs et méthodes de traitement pour des troubles associés à une lésion cérébrale traumatique
CN112930141B (zh)	2018-08-08	2025-05-23	米奈特朗尼克斯神经有限公司	用于沿着中枢神经系统进行治疗的系统、导管和方法
CN112770666A (zh) *	2018-10-05	2021-05-07	豪夫迈·罗氏有限公司	用于评估精神分裂症的数字生物标志物
WO2020070319A1 (fr) *	2018-10-05	2020-04-09	F. Hoffmann-La Roche Ag	Procédé, dispositif et système d'évaluation d'un trouble du spectre autistique
CA3129836A1 (fr) *	2019-02-14	2020-08-20	University Of North Texas Health Science Center At Fort Worth	Depistage base sur le sang pour la detection de maladies neurologiques dans des etablissements de soins primaires
WO2020206078A1 (fr) *	2019-04-05	2020-10-08	University Of North Texas Health Science Center At Fort Worth	Antidépresseurs pour le traitement ou la prévention des pertes de mémoire et/ou du déclin ou du dysfonctionnement cognitif liés à l'age
WO2021142163A1 (fr) *	2020-01-07	2021-07-15	Selonterra, Inc.	Traitement de la maladie d'alzheimer
US20240159776A1 (en) *	2021-03-11	2024-05-16	University Of North Texas Health Science Center At Fort Worth	Precision Medicine Approach to Targeting Neurodegeneration
EP4333980A4 (fr) *	2021-05-07	2025-07-16	Univ Of North Texas Health Science Center At Fort Worth	Test sanguin permettant de dépister la maladie de parkinson
US20240226035A1 (en) *	2021-05-07	2024-07-11	University Of North Texas Health Science Center At Fort Worth	Precision Medicine Approach to Treating Parkinson's Disease with a Monoamine Oxidase Inhibitor, an Antioxidant, or Both
US11275903B1 (en)	2021-05-13	2022-03-15	Retain Health, Inc	System and method for text-based conversation with a user, using machine learning
US12266449B2 (en)	2021-05-13	2025-04-01	Retain Health, Inc	System and method for text-based conversation with a user, using machine learning
WO2023168023A1 (fr)	2022-03-04	2023-09-07	Reset Pharmaceuticals, Inc.	Co-cristaux ou sels comprenant de la psilocine
WO2024074623A1 (fr) *	2022-10-05	2024-04-11	Westfälische Wilhelms-Universität Münster	Diagnostic, pronostic et traitement de maladies auto-immunes neuro-inflammatoires à l'aide de paramètres sanguins cellulaires et solubles
CN120870418B (zh) *	2025-09-22	2025-11-28	上海交通大学医学院附属第九人民医院	一种用于预测神经认知恢复延迟发生风险的试剂盒及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5192753A (en)	1991-04-23	1993-03-09	Mcgeer Patrick L	Anti-rheumatoid arthritic drugs in the treatment of dementia
WO1998040061A1 (fr)	1997-03-10	1998-09-17	Loma Linda University Medical Center	Utilisation d'enantiomeres r d'anti-inflammatoires non steroidiens pour la prevention de la maladie d'alzheimer
US6366813B1 (en) *	1998-08-05	2002-04-02	Dilorenzo Daniel J.	Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease
US6191154B1 (en)	1998-11-27	2001-02-20	Case Western Reserve University	Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US20070031853A1 (en) *	1999-02-22	2007-02-08	Variagenics, Inc., A Delaware Corporation	Gene sequence variations with utility in determining the treatment of neurological or psychiatric disease
US8101363B2 (en)	2000-12-14	2012-01-24	The Brigham And Women's Hospital, Inc.	Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes
US20030105082A1 (en) *	2001-12-03	2003-06-05	Murphy Greer Marechal	Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
JP2007513337A (ja)	2003-11-19	2007-05-24	サトリス，インコーポレイテッド	アルツハイマー病の診断方法、層化方法およびモニタリング方法
US20060094064A1 (en)	2003-11-19	2006-05-04	Sandip Ray	Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
EP1761191A4 (fr) *	2004-06-18	2008-05-14	Banner Health	Evaluation d'un traitement visant a reduire le risque de maladie cerebrale evolutive ou a ralentir le vieillissement cerebral
EP1797425A2 (fr)	2004-07-19	2007-06-20	University of Rochester	Biomarqueurs de maladie neurodegenerative
US9335331B2 (en) *	2005-04-11	2016-05-10	Cornell Research Foundation, Inc.	Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
US7575876B2 (en)	2005-10-27	2009-08-18	The University Of Washington	Biomarkers for neurodegenerative disorders
US20100233818A1 (en)	2006-02-17	2010-09-16	Atsuo Sekiyama	Biological Load Indicator and Method of Measuring Biological Load
DE102006027818A1 (de)	2006-06-16	2007-12-20	B.R.A.H.M.S. Aktiengesellschaft	In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
JP2010534676A (ja) *	2007-07-23	2010-11-11	シノシア・セラピューティクス	心的外傷後ストレス障害の治療
CA2717763A1 (fr) *	2008-03-04	2009-09-11	John Bilello	Diagnostic et surveillance de troubles depressifs bases sur une pluralite de panels de biomarqueurs
US8430816B2 (en)	2008-05-20	2013-04-30	General Electric Company	System and method for analysis of multiple diseases and severities
WO2009152607A1 (fr)	2008-06-16	2009-12-23	Ottawa Hospital Research Institute	Procédés et kits pour diagnostiquer une maladie neurodégénérative
EA201071324A1 (ru)	2008-08-27	2011-12-30	Х. Лундбекк А/С	Система и способы измерения профилей биомаркеров
US20100124756A1 (en)	2008-10-10	2010-05-20	Sandip Ray	Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
CN102460153A (zh) *	2009-04-06	2012-05-16	里奇诊断学股份有限公司	监控神经精神疾病治疗的生物标记
CA2709621A1 (fr)	2009-09-11	2011-03-11	Electrophoretics Limited	Marqueurs et methodes lies a l'evaluation de la maladie d'alzheimer
US20110105855A1 (en) *	2009-10-30	2011-05-05	Trustees Of Tufts College	Early detection of cognition impairment in elderly population
WO2011079299A1 (fr)	2009-12-23	2011-06-30	The George Washington University	Compositions et procédés d'identification de troubles du spectre autistique
US20110202284A1 (en)	2010-02-10	2011-08-18	Mcreynolds Cristopher	Novel groups of biomarkers for diagnosing alzheimer's disease
US20130273154A1 (en)	2011-03-02	2013-10-17	Joseph M. Fayad	Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
US20140147863A1 (en)	2010-05-14	2014-05-29	Rules-Based Medicine, Inc.	Methods and devices for diagnosing alzheimers disease
AU2012205798B2 (en) *	2011-01-10	2016-02-25	Takeda Pharmaceutical Company Limited	Methods and drug products for treating Alzheimer's disease
US20120238837A1 (en)	2011-03-16	2012-09-20	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	System, devices, and methods for real-time monitoring of cerebrospinal fluid for markers of progressive conditions
US20120295281A1 (en)	2011-05-18	2012-11-22	Bamburgh Marrsh Llc	Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
GB201110888D0 (en) *	2011-06-28	2011-08-10	Vib Vzw	Means and methods for the determination of prediction models associated with a phenotype
WO2013010003A1 (fr)	2011-07-12	2013-01-17	University Of Medicine And Dentistry Of New Jersey	Profils de biomarqueurs diagnostiques pour le dépistage et le diagnostic de la maladie d'alzheimer
US9211293B2 (en) *	2011-12-15	2015-12-15	Alkermes Pharma Ireland Limited	Opioid agonist antagonist combinations
KR20150006477A (ko) *	2012-05-09	2015-01-16	그래댈리스, 인코포레이티드	단일-뉴클레오타이드 ｋｒａｓ 돌연변이에 특이적인 이-기능성 짧은-헤어핀 ｒｎａ (ｂｉ-ｓｈｒｎａ)
US10634687B2 (en)	2012-07-16	2020-04-28	The Board Of Regents Of The University Of Texas System	Serum biomarker screen for the diagnosis of clinical and preclinical alzheimer's disease
CN104869993B (zh)	2012-10-25	2019-01-15	通用医疗公司	治疗阿尔茨海默病及相关疾病的组合疗法
US20190219599A1 (en)	2013-07-11	2019-07-18	University Of North Texas Health Science Center At Fort Worth	Blood-based screen for detecting neurological diseases in primary care settings
EP3751283A3 (fr)	2013-07-11	2021-03-24	University of North Texas Health Science Center at Fort Worth	Dépistage basé sur le sang pour la détection d'une maladie neurologique dans des installations de soins primaires
US20150086616A1 (en)	2013-09-20	2015-03-26	Steven Lehrer	Method for the prevention and treatment of alzheimer's disease
US20210215720A1 (en)	2013-11-26	2021-07-15	University Of North Texas Health Science Center At Fort Worth	Personalized medicine approach for treating cognitive loss
WO2015081166A1 (fr)	2013-11-26	2015-06-04	University Of North Texas Health Science Center At Fort Worth	Approche médicale personnalisée pour le traitement d'une perte cognitive
WO2016081941A1 (fr)	2014-11-21	2016-05-26	Caris Science, Inc.	Sondes oligonucléotidiques et leurs utilisations
WO2017223291A1 (fr)	2016-06-22	2017-12-28	University Of North Texas Health Science Center At Fort Worth	Test sanguin pour exclure par dépistage la présence d'amyloïde et de la maladie d'alzheimer
JP7105256B2 (ja)	2017-06-19	2022-07-22	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	伸長ヌクレオチド反復を含有する遺伝子の有害活性の低減のための化合物
JP7412003B2 (ja)	2018-01-18	2024-01-12	ユニバーシティーオブノーステキサスヘルスサイエンスセンターアットフォートワース	アルツハイマー病に罹患している患者の特定の亜集団を治療するためのｎｓａｉｄ及びドネペジルについてのコンパニオン診断

2014
- 2014-11-26 WO PCT/US2014/067562 patent/WO2015081166A1/fr not_active Ceased
- 2014-11-26 EP EP14865107.8A patent/EP3074525B1/fr active Active
- 2014-11-26 JP JP2016532622A patent/JP6364488B2/ja active Active
- 2014-11-26 CA CA2930874A patent/CA2930874A1/fr not_active Abandoned
- 2014-11-26 CA CA3089881A patent/CA3089881C/fr active Active
- 2014-11-26 AU AU2014354808A patent/AU2014354808A1/en not_active Abandoned
- 2014-11-26 US US15/037,492 patent/US11885816B2/en active Active
2018
- 2018-02-13 AU AU2018201062A patent/AU2018201062B2/en active Active
2020
- 2020-09-24 AU AU2020239715A patent/AU2020239715B2/en active Active
2021
- 2021-06-29 US US17/361,763 patent/US20210341494A1/en active Pending
2024
- 2024-01-12 US US18/412,046 patent/US20250020670A1/en active Pending

Also Published As

Publication number	Publication date
EP3074525A1 (fr)	2016-10-05
US20210341494A1 (en)	2021-11-04
EP3074525A4 (fr)	2017-08-23
US20160291036A1 (en)	2016-10-06
US20250020670A1 (en)	2025-01-16
CA3089881C (fr)	2024-04-02
WO2015081166A1 (fr)	2015-06-04
EP3074525B1 (fr)	2024-06-26
AU2020239715B2 (en)	2023-09-14
JP2017500551A (ja)	2017-01-05
AU2018201062B2 (en)	2020-07-02
JP6364488B2 (ja)	2018-07-25
US11885816B2 (en)	2024-01-30
CA2930874A1 (fr)	2015-06-04
AU2018201062A1 (en)	2018-03-08
CA3089881A1 (fr)	2015-06-04
AU2020239715A1 (en)	2020-10-15

Publication	Publication Date	Title
US20250020670A1 (en)	2025-01-16	Personalized medicine approach for treating cognitive loss
US20230314451A1 (en)	2023-10-05	Blood-based screen for detecting neurological diseases in primary care settings
Chen‐Plotkin et al.	2011	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
Shi et al.	2019	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
US20160033536A1 (en)	2016-02-04	Novel groups of biomarkers for diagnosing alzheimer's disease
Callahan et al.	2015	Predicting Alzheimer's disease development: a comparison of cognitive criteria and associated neuroimaging biomarkers
US20130116135A1 (en)	2013-05-09	Methods, Kits and Reagents for Diagnosing, Alding Diagnosis and/or Monitoring Progression of a Neurological Disorder
US20190219599A1 (en)	2019-07-18	Blood-based screen for detecting neurological diseases in primary care settings
O'Bryant et al.	2019	Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study
US20240142473A1 (en)	2024-05-02	Personalized medicine approach for treating cognitive loss
Ahmad et al.	2020	CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
JP2025118826A (ja)	2025-08-13	アルツハイマー病を判定するためのタンパク質マーカー
Dittrich et al.	2025	Evaluation of two plasma‐based proteotyping assays against APOE ε4 genotyping in a memory clinic setting: The Gothenburg H70 Clinical Studies
JP7539906B2 (ja)	2024-08-26	プライマリーケア環境において神経学的疾患を検出するための、血液ベースのスクリーニング法
WO2022187670A1 (fr)	2022-09-09	Approche médicale personnalisée permettant le traitement d'une perte cognitive
Delaby et al.	2025	Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progression
Öijerstedt	2021	Biomarkers in frontotemporal dementia: findings from the GENFI study
JP2026016513A (ja)	2026-02-03	アルツハイマー病を判定するためのタンパク質マーカー
US20220162701A1 (en)	2022-05-26	Blood-based screen for detecting neurological diseases in primary care settings
Class et al.	2016	Patent application title: NOVEL GROUPS OF BIOMARKERS FOR DIAGNOSING ALZHEIMER'S DISEASE Inventors: Cristopher Mcreynolds (Woodside, CA, US) David M. Rocke (Davis, CA, US) Lynn Kozma (Sunal, CA, US) Anton Wyss-Coray (Stanford, CA, US) Anton Wyss-Coray (Stanford, CA, US)

Legal Events

Date	Code	Title	Description
2018-03-15	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted